Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IZABRIGHT-BLADDER01 trial of izalontamab brengitecan versus platinum-based chemotherapy in metastatic urothelial cancer after immunotherapy
MOH_2025-09-21_014359Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of izalontamab brengitecan in transitional cell carcinoma (TCC) (3 arms), sponsored by Bristol Myers Squibb. Started Sep 2025; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on MOH_2025-09-21_014359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-09-21_014359.